68Ga-WL12

68Ga-WL12 is a peptide-based radiopharmaceutical designed for positron emission tomography (PET) imaging of programmed cell death ligand-1 (PD-L1) expression in tumors. The compound consists of the WL12 peptide, which binds specifically to PD-L1, conjugated with a chelator (such as NOTA or DOTAGA) and radiolabeled with gallium-68. This agent enables noninvasive quantification and visualization of PD-L1 expression in vivo, supporting patient selection and monitoring for immunotherapies targeting the PD-1/PD-L1 axis. Preclinical studies demonstrated high affinity for PD-L1 and favorable pharmacokinetics; first-in-human trials have shown safety, feasibility, and correlation between tracer uptake and tumor PD-L1 levels in patients with advanced non–small cell lung cancer[3][4][5][7].

Other names

gallium Ga 68-WL12